Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV vs SC Nadroparin for Thromboprophylaxis in ICU
NCT04982055Phase 4Completed
- Sponsor
- Clinique Saint-Pierre Ottignies
- Start
- Apr 2015
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of nadroparin in venous thromboembolism (VTE) (2 arms), sponsored by Clinique Saint-Pierre Ottignies. Primary endpoint: Peak anti-Xa activity at 4 hours. Started Apr 2015; status: completed.
02
Drugs
nadroparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04982055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982055.